PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
PDS Biotechnology Corporation (PDSB)
Last pds biotechnology corporation earnings: 11/7 06:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City. Details of the presentation are as follows: H.C. Wainwright 26th Annual Global Investment ConferenceDate: Tuesday, September 10, 2024 Event: PresentationTime: 2:00-2:30 PM ET To register for the in-person event, please click here. The presentation will be available for on-demand viewing starting on September 10, 2024, at 2:00 p.m. ET by clicking here. Following the event, an archived replay of the presentation will be available in the Investor Relations section of the Compa
Show less
Read more
Impact Snapshot
Event Time:
PDSB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PDSB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PDSB alerts
High impacting PDS Biotechnology Corporation news events
Weekly update
A roundup of the hottest topics
PDSB
News
- PDS Biotech Leadership to Participate in March ConferencesGlobeNewswire
- PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck CancerGlobeNewswire
- PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA OncologyGlobeNewswire
PDSB
Earnings
- 11/14/24 - In-Line
PDSB
Sec Filings
- 3/7/25 - Form 8-K
- 3/3/25 - Form 4
- 3/3/25 - Form 4
- PDSB's page on the SEC website